Altre lingue Revive Therapeutics Ltd.

Azioni

RVV

CA7615161030

Mercato chiuso - Canadian Securities Exchange Altri mercati azionari 19:23:32 26/04/2024			Variaz. 5gg	Var. 1 gen.
0,03 ^CAD	+20,00%		0,00%	0,00%

18/04	Revive Therapeutics Ltd. annuncia l'accettazione da parte della FDA della richiesta di incontro per il prodotto diagnostico Long COVID	CI
02/04	Revive Therapeutics Ltd. fornisce un aggiornamento sullo studio clinico sulla psilocibina per il disturbo da uso di metamfetamina	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

FDA Grants Revive Therapeutics Type C Meeting Request For Bucillamine Study to Treat Long COVID	23/04
Revive Therapeutics Brief: Announcing Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID	23/04
Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID	23/04
Revive Therapeutics Announced FDA Acceptance of Meeting Request for Long COVID Diagnostic Product	18/04
Revive Therapeutics Brief: Announcing FDA Acceptance of Meeting Request for Long COVID Diagnostic Product	18/04
Revive Therapeutics Announces FDA Acceptance of Meeting Request for Long COVID Diagnostic Product	18/04
Revive Therapeutics Ltd. Announces FDA Acceptance of Meeting Request for Long COVID Diagnostic Product	18/04
Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder	02/04
Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder	02/04
Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder	02/04
Revive Therapeutics Ltd. Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder	02/04
Revive Therapeutics Submits Type C Meeting Request Package to FDA for Clinical Study of Bucillamine to Treat Long COVID	27/03
Revive Therapeutics Submits Type C Meeting Request Package to FDA for Clinical Study of Bucillamine to Treat Long COVID	27/03
Revive Therapeutics Submits Type C Meeting Request Package to FDA for Clinical Study of Bucillamine to Treat Long COVID	27/03
Revive Therapeutics : Document	20/03
Revive Therapeutics : Document	20/03
Revive Therapeutics to Submit Type C Meeting Request with FDA for Bucillamine to Treat Long COVID	19/03
Revive Therapeutics To Submit Type C Meeting Request with FDA for Bucillamine to Treat Long COVID	19/03
Revive Therapeutics Ltd. Announces to Submit Type C Meeting Request with FDA for Bucillamine to Treat Long COVID	19/03
Revive Therapeutics Provides Corporate Update	12/03

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Revive Therapeutics Ltd.

Azioni

RVV

CA7615161030

Altre lingue

Filtri